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Varicella 
Disease
Herpes virus (DNA)
Primary infection results in varicella (chickenpox)
Short survival in environment
Varicella Zoster Virus
MMWR 2007;56(RR-04)
Respiratory transmission of virus
Replication in nasopharynx and regional lymph nodes
Primary viremia 4 to 6 days after infection
Multiple tissues, including sensory ganglia, infected during 
viremia
Varicella Pathogenesis
MMWR 2007;56(RR-04)
 Incubation period: 14 to 16 days (10–21 days)
Mild prodrome for 1 to 2 days (adults)
Rash generally appears first on the head; most concentrated 
on the trunk
Successive crops over several days with lesions present in 
several stages of development
Varicella (Chickenpox) Clinical Features 
MMWR 2007;56(RR-04)
Bacterial infection of lesions
Hemorrhagic varicella
CNS manifestations
Pneumonia (primary viral or secondary bacterial)
Congenital varicella
Perinatal varicella
Varicella Complications
MMWR 2007;56(RR-04)
Varicella with a secondary bacterial infection
Persons older than 15 years
 Infants younger than 1 year
 Immunocompromised persons
Newborns of women with rash onset within 5 days before to 
48 hours after delivery
Increased Risk of Complications of Varicella
MMWR 2007;56(RR-04)
Reservoir Human
Transmission Person to person – respiratory tract secretions 
Direct contact with lesions
Temporal Pattern Peak in late winter and spring (U.S.) 
Communicability 1 to 2 days before until lesions have formed crusts 
May be longer in immunocompromised
Varicella Epidemiology
MMWR 2007;56(RR-04)
Varicella-
containing 
Vaccines
Vaccines for the Prevention of Varicella (Chickenpox) 
Product ACIP Recommended Age Indications ACIP Abbreviation 
Varivax 12 months and older VAR
ProQuad 12 months through 12 years MMRV
 In a pre-licensure clinical trial, 
2 doses of vaccine were: 
• 98% effective at preventing 
any form of varicella
• 100% effective against severe 
varicella
 In post-licensure studies, 2 
doses of vaccine were:
• 88% to 98% effective at 
preventing all varicella
Varicella Vaccine 
Immunogenicity and Efficacy
CDC Chickenpox About the Vaccine for Health Care Professionals www.cdc.gov/vaccines/vpd/varicella/hcp/about-vaccine.html, accessed 8/13/2018
 Storage: 
• Lyophilized vaccine: In the freezer between -50°C and -15°C 
(-58°F and +5°F)
• Diluent: At room temperature (68°F to 77°F, 20°C to 25°C) or in the 
refrigerator (36°F to 46°F, 2°C to 8°C) 
 Preparation: Reconstitute the vaccine with the diluent supplied by 
the manufacturer just before administering 
 Administration: Subcut injection
• Site: Fatty tissue of the anterolateral thigh or upper outer triceps 
of the arm 
• Needle length and gauge: 5/8-inch, 23- to 25-gauge needle
Varicella-Containing Vaccines: 
Varivax (Var) and ProQuad (MMRV)
ProQuad package insert www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm123793.pdf, accessed 8/12/2018
Varivax package insert www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142812.pdf, accessed 8/12/2018 
Varicella Vaccine 
and Clinical 
Considerations
Written documentation of age-appropriate vaccination
 Laboratory evidence of immunity or laboratory confirmation 
of varicella disease
U.S.-born before 1980*
Health care provider diagnosis or verification of varicella 
disease
History of herpes zoster based on health care provider 
diagnosis
Acceptable Evidence of Varicella Immunity
*Birth year immunity criterion does not apply to health care personnel or pregnant women
MMWR 2007;56(RR-4):16-17
 Routine recommendations:  
 Dose 1 at 12–15 months of 
age
 Dose 2 at 4–6 years of age
 Minimum interval between 
doses is 3 months for 
children 12 years of age and 
younger 
ACIP Immunization Recommendations: 
Young Children 
Assess all persons 13 years of age and older for evidence of 
varicella immunity
Administer 2 doses separated by at least 4 weeks to those 
without evidence of immunity 
2nd dose recommended for persons of any age who have only 
received 1 dose
• Do not repeat 1st dose because of extended interval between 
doses
ACIP Immunization Recommendations: 
Adolescents and Adults 
Assess all health care personnel for evidence of immunity
Vaccination is recommended for all susceptible health care 
personnel
• Give 2 doses, 4 weeks apart to susceptible persons
Prevaccination serologic screening might be cost-effective
Postvaccination testing NOT recommended 
Varicella Vaccination and Health Care Personnel
CDC and ACIP do NOT recommend antibody testing AFTER
varicella vaccination
• Commercially available laboratory tests for varicella antibody 
are usually not sufficiently sensitive to detect vaccine–induced 
antibody
• Even though they are generally sensitive to deduce antibodies 
resulting from varicella zoster virus infection
Documented receipt of 2 doses of varicella vaccine SUPERSEDES 
results of subsequent serologic testing     
Varicella Serology and Post Vaccination 
Single-antigen varicella vaccine may be administered to 
persons with isolated humoral immunodeficiency
Consider varicella vaccination for: 
• HIV-infected children with CD4 count of 15% or higher
• HIV-infected older children and adults with CD4 count of 
200 or higher
Varicella Vaccine and Immunocompromised 
Persons
Severe allergic reaction to a vaccine component or following a 
prior dose
Pregnancy or planned pregnancy within 4 weeks*
 Immunosuppression
 Family history of altered immunocompetence
Varicella and MMRV Vaccine Contraindications
*ACIP off-label recommendation 
MMWR 2007;56(RR-04)
General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP)  Contraindications and Precautions 
section www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html, accessed 08/12/2018 
Moderate or severe acute illness with or without fever
Recent blood product 
• Varicella or MMRV vaccines should not be administered for  
3–11 months after receipt of antibody-containing blood 
products
Receipt of specific antiviral drugs (acyclovir, famciclovir, or 
valacyclovir) 24 hours before vaccination 
• Avoid use of these antiviral drugs for 14 days after vaccination
Use of aspirin or aspirin-containing products
Varicella and MMRV Vaccine Precautions
MMWR 2007;56(RR-04)\
General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) Contraindications and Precautions 
section www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html, accessed 08/12/2018 
MMRV only: personal or family (i.e., sibling or parent) history 
of seizures of any etiology
These children generally should be vaccinated with separate 
MMR and varicella vaccines
Varicella-Containing Vaccines Precautions 
MMWR 2007;56(RR-04)
 Local reactions (pain, erythema) 
• Varicella: 
o19% (children)
o24% (adolescents and adults) 
• Rash: 3%–4%
• May be maculopapular rather than vesicular
• Average 5 lesions
Systemic reactions not common
Varicella Adverse Reactions
MMWR 2007;56(RR-04)
 Fever is more common in the 5–12 days after vaccination with 
MMRV (22%) than with MMR + VAR (15%)
Data from CDC Vaccine Safety Datalink sites indicate the rate 
of febrile seizures following MMRV (9 per 10,000 vaccinated) 
was approximately 2 times higher than among those receiving 
MMR + VAR at the same visit (4 per 10,000 vaccinated)
Merck postlicensure surveillance has identified a similar trend
Adverse Reactions 
MMRV and MMR + VAR 
MMWR 2007;56(RR-04)
 For the first dose of measles, mumps, rubella, and varicella 
vaccines at age 12–47 months, either MMR vaccine and varicella 
vaccine or MMRV vaccine may be used
 Providers who are considering administering MMRV vaccine 
should discuss the benefits and risks of both vaccination options 
with the parents or caregivers
 Unless the parent or caregiver expresses a preference for MMRV 
vaccine, CDC recommends that separate MMR vaccine and 
varicella vaccine should be administered for the first dose for 
children 12–47 months of age
MMRV Vaccine
MMWR 2010;59(RR-3)
Administer MMRV: 
• For the second dose of measles, mumps, rubella, and varicella 
vaccines at age 15 months through 12 years
• For the first dose at age 48 months or older
MMRV Vaccine
MMWR 2010;59(RR-3)
Zoster 
Disease 
Reactivation of varicella zoster virus 
Associated with:
• Aging
• Immunosuppression
• Intrauterine exposure
• Varicella disease younger than 18 months of age
Herpes Zoster (Shingles)
MMWR 2008;57(RR-5)
Postherpetic neuralgia (PHN)
Dissemination with generalized skin eruptions and 
involvement of the central nervous system, lungs, liver, and 
pancreas
Ophthalmic zoster
Complications of Herpes Zoster
MMWR 2008;57(RR-5)
Approximately 1 million episodes occur annually in the United 
States 
 Lifetime risk of zoster estimated to be 32%
50% of persons living until age 85 will develop zoster
Herpes Zoster 
CDC Shingles (Herpes Zoster) Overview https://www.cdc.gov/shingles/about/overview.html
Zoster involving the ophthalmic division of the trigeminal nerve 
Zoster Vaccines 
Vaccines for Prevention of Zoster (Shingles) 
*Zostavax is FDA-approved for persons 50 years of and older 
Product
(ACIP Abbreviation) Type
ACIP Age 
Recommendations
Zostavax (ZVL) Live, attenuated 60 years of age and older*
Shingrix (RZV) Inactivated, adjuvanted 50 years of age and older 
Vaccine recipients 60 to 80 years of age had 51% fewer 
episodes of zoster
• Efficacy declines with increasing age
• Significantly reduces the risk of postherpetic neuralgia
• Reduces the risk of zoster 69.8% in persons 50 through          
59 years of age
Live Zoster Vaccine (ZVL) Efficacy 
CDC Zostavax Information for Healthcare Professionals www.cdc.gov/vaccines/vpd/shingles/hcp/zostavax/about-vaccine.html
Efficacy for the prevention of zoster:
• 96.6% in adults age 50 to 59 years
• 97.4% in adults age 60 to 69 years
• 91.3% in adults age 70 years and older
The efficacy for the prevention of postherpetic neuralgia 
(PHN) was: 
• 91.2% in adults age 50 years and older
• 88.8% in adults age 70 years and older
RZV Vaccine Efficacy 
CDC Shingrix Information for Healthcare Professionals https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/about-vaccine.html, accessed 8/12/2018 
 Storage: 
• Lyophilized vaccine: In the freezer between -50°C and -15°C (-58°F 
and +5°F)
• Diluent: At room temperature (68°F to 77°F, 20°C to 25°C) or in the 
refrigerator (36°F to 46°F, 2°C to 8°C) 
 Preparation: Reconstitute the vaccine with the diluent supplied by 
the manufacturer just before administering 
 Schedule: 1 dose 
 Administration: Subcut injection
• Site: Fatty tissue of the upper outer triceps of the arm 
• Needle length and gauge: 5/8-inch, 23- to 25-gauge needle
Zoster Vaccine: Zostavax (ZVL)
Zostavax package insert www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm132831.pdf, accessed 8/12/2018
 Storage: Store vaccine AND diluent in the refrigerator between 2°C and 8°C 
(36°F and 46°F) 
 Preparation: Reconstitute the vaccine with the diluent (adjuvant) supplied by 
the manufacturer just before administering 
• If not used immediately, the reconstituted vaccine may be stored in the 
refrigerator and use it within 6 hours of reconstitution 
• If not used, 
 Schedule: 2 doses, 2 to 6 months apart
 Route: IM Injection 
• Site: Deltoid or the thigh may be used if necessary
• Needle gauge and length: 23- to 25-gauge needle, length varies by age/weight
 RZV may be administered during the same clinical encounter as other vaccines 
Zoster Vaccine: Shingrix (RZV)
MMWR 2018;67(3):103–108
Due to high levels of demand for GSK’s 
Shingrix vaccine, GSK has implemented 
order limits and providers have 
experienced shipping delays
Order limits and shipping delays will 
continue throughout 2019
GSK increased the U.S. supply during 
2018 and plans to make even more 
doses available in 2019 
Vaccine Supply: Shingrix
CDC Current Vaccine Shortages and Delays www.cdc.gov/vaccines/hcp/clinical-resources/shortages.html, accessed 8/27/2019 
Your Email Address 
Clinical 
Considerations 
Administer 2 doses of Shingrix, 2 to 6 months apart, for adults 
50 years of age and older  
Shingrix is preferred to Zostavax for persons 60 years and older
Whether or not they report a: 
• History of zoster disease 
• Prior dose of Zostavax or varicella vaccine  
oSeparate varicella-containing vaccines and Shingrix by at least 8 weeks 
• History of chronic medical condition, unless a contraindication 
or precaution exists 
ACIP Zoster Immunization Recommendations
MMWR 2018;67(3):103–108
ACIP considers people born in the United States prior to 1980 
immune to varicella
When vaccinating adults 50 years of age and older, there is no 
need to: 
• Screen for a history of varicella (chickenpox) infection OR 
• Conduct laboratory testing for serologic evidence of prior 
varicella infection
• More than 99% of adults age 50 years and older worldwide 
have been exposed to varicella zoster virus
Zoster Vaccination: 
Patients Who Do Not Report A Prior Episode of Varicella 
MMWR 2018;67(3):103–108
 If tested and varicella-negative:
• Administer 2 doses of single-antigen varicella vaccine (Varivax) 
separated by at least 4 weeks 
• Followed by 2 doses of RZV, separated by 2–6 months 
oSeparate the 2nd (last) dose of varicella and 1st dose of RZV 
by at least 8 weeks 
Zoster Vaccine and Serology
MMWR 2008;57(RR-5)
History of severe allergic reaction, such as anaphylaxis, to any 
component of a vaccine or after a previous dose of Shingrix
Moderate to severe illness, including an acute episode of 
herpes zoster
• Shingrix is not a treatment for herpes zoster or postherpetic
neuralgia (PHN)
Shingrix has not been studied in pregnant women or women 
who are breastfeeding. Providers should consider delaying 
Shingrix vaccination for these women
RZV Contraindications and Precautions 
CDC Shingrix Recommendations www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html, accessed 8/12/2018
 Administer RZV to persons:
• Taking low-dose immunosuppressive therapy (e.g., <20 mg/day of 
prednisone or equivalent or using inhaled or topical steroids)
• Anticipating immunosuppression
• Who have recovered from an immunocompromising illness 
 ACIP has not yet made recommendations regarding administering 
RZV to persons on moderate to high doses of immunosuppressive 
therapy 
RZV and Immunosuppressive Therapy 
MMWR 2018;67(3):103–108
 History of a life-threatening or severe allergic reaction to gelatin, 
the antibiotic neomycin, or any other component of ZVL
 A weakened immune system because of: 
• HIV/AIDS or another disease that affects the immune system
• Treatment with drugs that affect the immune system
• Cancer treatment such as radiation or chemotherapy
• Cancer affecting the bone marrow or lymphatic system, such as 
leukemia or lymphoma
 Women who are or might be pregnant
• Women should not become pregnant until at least 4 weeks* after 
getting ZVL
Zostavax (ZVL) Contraindications
*ACIP off-label recommendation
MMWR 2008;57(RR-5)
Moderate or severe acute illness
Current treatment with an antiviral drug active against herpes 
viruses
• Discontinue at least 24 hours before administration of zoster 
vaccine
• Should not be taken for at least 14 days after vaccination
Recent receipt of a blood product is NOT a precaution
Zostavax (ZVL) Vaccine Precautions
MMWR 2008;57(RR-5)
 Local reactions–34% (pain, erythema)
No increased risk of fever
No serious adverse reactions identified
Zostavax (ZVL)  Adverse Reactions
MMWR 2008;57(RR-5)
Local reactions 49%
Local reactions–Grade 3 9.4%
Systemic reactions (headache, malaise, fatigue)
Systemic reactions (headache, malaise, fatigue)–Grade 3
45–78%
11%
RZV (Shingrix) Adverse Reactions
MMWR 2018;67(3):103–108
Educate patients regarding:
• Potential adverse reactions, including 
injection site and systemic reactions
• The need for a second dose–even if s/he 
has an adverse reaction
Offer comfort measures and 
strategies 
Adverse Reactions after Shingrix
CDC unpublished photo. Used with the permission of the patient. 
Resources 
There is a VIS for: 
• RZV (Shingrix)  
• Var (Varicella)
• MMRV (ProQuad)
• ZVL (Zostavax)
Give the parent or patient 
the appropriate VIS for the 
product that will be 
administered 
Vaccine Information Statements 
Vaccine Information Statements https://www.cdc.gov/vaccines/hcp/vis/vis-statements/shingles.html, accessed 8/12/2018
Resources and references are available on the webinar web page 
Varicella and Zoster Vaccine Resources and 
References 
